Johnson & Johnson Announces RYBREVANT Plus LAZCLUZE Show Statistically Significant And Clinically Meaningful Improvement In Overall Survival Versus Osimertinib; Median Overall Survival Improvement Expected To Exceed One Year; First And Only Regimen...
Johnson & Johnson Announces RYBREVANT Plus LAZCLUZE Show Statistically Significant And Clinically Meaningful Improvement In Overall Survival Versus Osimertinib; Median Overall Survival Improvement Expected To Exceed One Year; First And Only Regimen...
Johnson & Johnson Announces RYBREVANT Plus LAZCLUZE Show Statistically Significant And Clinically Meaningful Improvement In Overall Survival Versus Osimertinib; Median Overall Survival Improvement Expected To Exceed One Year; First And Only Regimen With A Survival Benefit Over Current Standard Of Care In First-line Treatment Of EGFR-Mutated Lung Cancer
強生宣佈RYBREVANt聯合LAZCLUZE在總體生存率上與奧希替尼相比顯示出統計學上顯著和臨牀意義改善；預計中位總體生存率改善將超過一年；在EGFR突變性肺癌的一線治療中首個也是唯一一個具有生存優勢的方案，超過了現有標準治療。
Median overall survival improvement expected to exceed one year
預計中位總體生存率改善將超過一年
First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer
首個也是唯一一個具有生存優勢的方案，超過了現有標準治療，適用於EGFR突變性肺癌的一線治療
RARITAN, N.J., Jan. 7, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study, evaluating RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. The chemotherapy-free combination regimen met the final pre-specified secondary endpoint of OS and demonstrated clinically meaningful and statistically significant improvement in OS versus the current standard of care osimertinib. Improvement in median OS is expected to exceed one year.
新澤西州RARITAN，2025年1月7日 /PRNewswire/ -- 強生（紐交所：JNJ）今天宣佈針對癌症治療 gold 標準終點中的總體生存率（OS）的積極頂線結果，來自於第三階段MARIPOSA研究，該研究評估RYBREVANt（阿米萬單抗-vmjw）聯合LAZCLUZE（拉澤替尼）作爲治療局部晚期或轉移性非小細胞肺癌（NSCLC）患者的一線療法，這些患者具有表皮生長因數受體（EGFR）外顯子19缺失（ex19del）或L858R替代突變。該無化療聯合方案滿足最終預先規定的OS二級終點，並顯示出與現有標準治療奧希替尼相比，在OS上具有臨牀意義和統計學上顯著的改善。中位OS的改善預計將超過一年。
